Video

Dr Sharon Phares Explores Equity Issues Regarding HTAs Among Women

Author(s):

Sharon Phares, PhD, MPH, chief scientific officer of the National Pharmaceutical Council, describes the lasting equity concerns regarding the use of health technology assessments (HTAs) for women.

Sharon Phares, PhD, MPH, chief scientific officer of the National Pharmaceutical Council, describes the lasting equity concerns regarding the use of health technology assessments (HTAs) for women.

What about other equity issues? Are HTAs considering equity systematically?

Phares: So, currently, they are not. There has been a lot of discussion in the HTA community around trying to address disparity in a better way. For instance, a medication that is found to be less valuable may be a medication that's more useful for someone who is poor because they have to take it less often. So, you don't have as many scheduling issues or need the same handling, like they don't need a special refrigerated space for that if you're sharing housing with other people or if you have homelessness issues. But also, to be able to address how medications impact the outcomes of different groups differently. So, this is where we need more real world evidence to come into play to really look at differences by various groups.

Related Videos
Dr Emma Achola-Kothani
Marla Black Morgan, MD, Phoebe Neurology Associates
Christine Funke, MD
Toby Maher, MD, PhD, professor of clinical medicine, Keck School of Medicine at USC
Nini Wu, MD, Navista
Fred Locke, MD, Moffitt Cancer Center and Research Institute
Dr Emma Achola-Kothari
Matthew Viggiano, MD, internal medicine resident, Temple University Hospital
Krunal Patel, MD, pulmonary and critical care fellow, Temple University Hospital
M. Bradley Drummond, MD, MHS, professor of medicine, University of North Carolina at Chapel Hill
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo